Literature DB >> 19327515

Does preoperative atrial fibrillation increase the risk for mortality and morbidity after coronary artery bypass grafting?

Niv Ad1, Scott D Barnett, Constance K Haan, Sean M O'Brien, Sarah Milford-Beland, Alan M Speir.   

Abstract

OBJECTIVES: Preoperative atrial fibrillation has been associated with less favorable outcomes in patients undergoing coronary artery bypass grafting. However, it was never investigated in a large cohort of patients using a national database. This study aims to (1) identify the effect of atrial fibrillation on operative mortality and morbidity in patients undergoing isolated coronary artery bypass grafting and (2) identify the potential effect of atrial fibrillation on patients with decreased left ventricular ejection fraction (<or=40%).
METHODS: The Society of Thoracic Surgeons National Adult Cardiac Surgery Database was used for patients with coronary artery disease undergoing isolated coronary artery bypass grafting (n = 281,567). The association between atrial fibrillation and outcomes was estimated within 3 categories of low (ejection fraction, <40%), moderate (ejection fraction, 40%-55%), or normal (ejection fraction, >55%) systolic function.
RESULTS: Patients with atrial fibrillation were found to be older and have a higher incidence of comorbidities. A higher incidence of all major complications and mortality after surgical intervention was documented. An interaction between atrial fibrillation and an ejection fraction of greater than 40% for mortality, stroke, prolonged ventilation, and prolonged length of stay was identified.
CONCLUSIONS: Our findings suggest that preoperative atrial fibrillation is associated with an increased risk for perioperative mortality and morbidity in patients undergoing coronary artery bypass grafting. The negative effect of atrial fibrillation might be more significant in patients undergoing coronary artery bypass grafting with an ejection fraction of greater than 40%. Both the EuroSCORE and, until recently, the Society of Thoracic Surgeons risk calculator do not include atrial fibrillation as a potential risk modifier; however, based on this study, it should be identified as a variable to be investigated and incorporated into future risk calculators.

Entities:  

Mesh:

Year:  2009        PMID: 19327515     DOI: 10.1016/j.jtcvs.2008.09.050

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  10 in total

Review 1.  Management of Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Grafting: Review of the Literature.

Authors:  Ali J Khiabani; Taylan Adademir; Richard B Schuessler; Spencer J Melby; Marc R Moon; Ralph J Damiano
Journal:  Innovations (Phila)       Date:  2018 Nov/Dec

2.  Atrial Fibrillation and Stroke Risk After Coronary Artery Bypass Grafting Surgery.

Authors:  F Hornero; E Martín; A V Mena-Durán; R Rodríguez; M Castellà; C Porras; B Romero; L Maroto; Pérez de la Sota E; Mª Echevarría; M J Dalmau; L Díez; J Buendía; F Enríquez; M Castaño; G Reyes; A Ginel; M Pérez; J Barquero; A Jiménez; E Castedo; G Pradas; M Gómez
Journal:  J Atr Fibrillation       Date:  2013-10-31

3.  Preoperative atrial fibrillation is an independent risk factor for mid-term mortality after concomitant aortic valve replacement and coronary artery bypass graft surgery.

Authors:  Akshat Saxena; Diem Dinh; Jim Dimitriou; Christopher Reid; Julian Smith; Gilbert Shardey; Andrew Newcomb
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-01-03

4.  Effect of novel modified bipolar radiofrequency ablation for preoperative atrial fibrillation combined with off-pump coronary artery bypass grafting surgery.

Authors:  Zhaolei Jiang; Nan Ma; Min Tang; Hao Liu; Fangbao Ding; Hang Yin; Ju Mei
Journal:  Heart Vessels       Date:  2014-05-13       Impact factor: 2.037

5.  Prognosis and management of new-onset atrial fibrillation in critically ill patients.

Authors:  Jun Qian; Lijun Kuang; Fei Chen; Xuebo Liu; Lin Che
Journal:  BMC Cardiovasc Disord       Date:  2021-05-05       Impact factor: 2.298

6.  SYNTAX score predicts postoperative atrial fibrillation in patients undergoing on-pump isolated coronary artery bypass grafting surgery.

Authors:  Çetin Geçmen; Gamze Babür Güler; Emrah Erdoğan; Suzan Hatipoğlu; Ekrem Güler; Fatih Yılmaz; Tuba Unkun; Murat Cap; Ruken Bengi Bakal; Tülay Bayram; Rezzan Deniz Acar; Özkan Candan; Nihal Özdemir
Journal:  Anatol J Cardiol       Date:  2015-11-18       Impact factor: 1.596

7.  Clinical Insights to Complete and Incomplete Surgical Revascularization in Atrial Fibrillation and Multivessel Coronary Disease.

Authors:  Michal Pasierski; Jakub Staromłyński; Janina Finke; Radoslaw Litwinowicz; Grzegorz Filip; Adam Kowalówka; Wojciech Wańha; Michalina Kołodziejczak; Natalia Piekuś-Słomka; Andrzej Łoś; Sebastian Stefaniak; Wojciech Wojakowski; Marek Jemielity; Jan Rogowski; Marek Deja; Dariusz Jagielak; Krzysztof Bartus; Silvia Mariani; Tong Li; Matteo Matteucci; Daniele Ronco; Federica Jiritano; Dario Fina; Gennaro Martucci; Paolo Meani; Giuseppe Maria Raffa; Artur Słomka; Pietro Giorgio Malvidni; Roberto Lorusso; Michal Zembala; Piotr Suwalski; Mariusz Kowalewski
Journal:  Front Cardiovasc Med       Date:  2022-06-15

8.  Bedside tool for predicting the risk of postoperative atrial fibrillation after cardiac surgery: the POAF score.

Authors:  Giovanni Mariscalco; Fausto Biancari; Marco Zanobini; Marzia Cottini; Gabriele Piffaretti; Matteo Saccocci; Maciej Banach; Cesare Beghi; Gianni D Angelini
Journal:  J Am Heart Assoc       Date:  2014-03-24       Impact factor: 5.501

9.  Ascending aortic aneurysm repair and surgical ablation for atrial fibrillation.

Authors:  Berhane Worku; Iosif Gulkarov; Charles A Mack; Leonard N Girardi; Arash Salemi
Journal:  J Cardiothorac Surg       Date:  2015-11-26       Impact factor: 1.637

10.  Myocardial protective effects of dexmedetomidine in patients undergoing cardiac surgery: A meta-analysis and systematic review.

Authors:  Zheng Gong; Li Ma; Yu-Lin Zhong; Jun Li; Jing Lv; Yu-Bo Xie
Journal:  Exp Ther Med       Date:  2017-03-13       Impact factor: 2.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.